1. Scrip
  2. >>Business
  3. >>Strategy

Deloitte Sees Rising Industry ROI, But Challenge In Sustaining It

 
• By Joseph Haas

Projected return on investment for the 20 pharmas with the highest R&D spend is expected to rise for the second straight year, Deloitte says. How to get there is less clear.

Deloitte sees ROI for pharma in R&D but a challenge sustaining the trend (Shutterstock)

In its annual report analyzing the biopharmaceutical sector’s rate of return on innovation, Deloitte says the industry is expected to continue seeing increasing ROI, but that continuing on that positive path will require companies to be “brave and bold.” It describes such an approach as one that pursues originality, such as novel mechanisms of action and unmet medical needs, rather than trying to do what has worked well for competitors.

Key Takeaways
  • Deloitte found that the 20 pharma companies with the highest R&D spend increased internal return on investment for the second straight year.

In the 15th edition of its Measuring the return from pharmaceutical innovation report, released on 25 March, Deloitte said the...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Strategy

Sanofi’s Sarclisa Wins Another EU Multiple Myeloma Nod In Its Unequal Battle With J&J’s Darzalex

 
• By Sushmita Panda

The French drugmaker's anti-CD38 antibody has racked up another approval in first-line multiple myeloma, but it marks a small victory while the company develops a subcutaneous version to help level the field with J&J’s Darzalex.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By Manas Mishra

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By Vibha Ravi

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis

S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas

 
• By Jessica Merrill

Ultragenyx updated investors on interactions with the US FDA on gene therapy, while new drug launches were themes for Ionis and Organon in Q2 reporting.

More from R&D

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By Kevin Grogan

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

Vertex’s Pain Drug Failure Adds To Investor Doubts

 
• By Andrew McConaghie

A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.

Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom

 
• By Manas Mishra

Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.